HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on returning blood cancers
Disease control OngoingThis early-stage study tests a new treatment for people with certain B-cell blood cancers (like lymphomas and leukemias) that have come back. The treatment involves taking a patient's own white blood cells, adding a new gene to help them find and kill cancer cells, and giving the…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 07:03 UTC
-
New drug combo aims to stop aggressive lymphomas from coming back
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. About 363 adults with these aggressive lymphomas will receive either the usual chemo or the usual chemo plus venetoclax. The goal is …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
Immunotherapy-Chemo combo shows promise for tough lymphoma
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can help people with aggressive B-cell non-Hodgkin lymphoma. About 30 adults with advanced stages of the disease are taking part. The main goal is to see how long the c…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Could an oral drug boost chemo for seniors with lymphoma?
Disease control OngoingThis study looks at whether adding an oral medication (CC-486, or oral azacitidine) to a standard reduced-dose chemo regimen (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas. The goal is to see if the combination improves how long pa…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Promising lymphoma combo study pulled before it even started
Disease control TerminatedThis study planned to test a combination of three drugs (rituximab, venetoclax, and bortezomib) in adults with a type of aggressive lymphoma that had come back or stopped responding to standard treatment. The goal was to see if the combination could shrink or control the cancer. …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 04, 2026 16:31 UTC